# A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

> **NCT01871805** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 134 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Alectinib

## Key facts

- **NCT ID:** NCT01871805
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-30
- **Primary completion:** 2014-10-24
- **Final completion:** 2017-08-31
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01871805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01871805, "A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01871805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*